Mohamad Haqiqian
PET Radiopharmacy Production & QC Analyst, Radiation Safety Supervisor Curium Pharma
Dr Mohamad Haqiqian is a radiopharmaceutical and radiation safety specialist at University College London Hospitals (UCLH) and Curium Pharmaceuticals, specialising in radiopharmaceutical manufacturing, development, radiation safety, and applied medical physics. He holds a PhD, MSc, and BSc in Nuclear Engineering and Medical Radiation Engineering. His research includes in vivo and in vitro studies investigating combination therapies integrating nanotechnology and radiation therapy for pancreatic cancer. He has extensive experience in GMP-compliant radiopharmaceutical manufacturing, quality assurance, radiation physics, dosimetry, and regulatory compliance. He actively contributes to radiation safety training, supporting innovation and operational excellence in nuclear medicine and targeted radiopharmaceuticals
Seminars
Experience a fast-paced debate, where isotope specialists will each present the strongest case for their radionuclide before joining a moderated discussion comparing clinical evidence, manufacturing readiness, supply considerations and commercial potential. Hear contrasting perspectives, challenge conventional thinking and take part in the discussion as the audience helps determine which isotope will define the next five years of TRP development.
- Comparing the scientific, clinical, manufacturing and commercial advantages of emerging isotopes including Actinium-225, Lead-212, Copper-67, Terbium, Astatine-211 and Lutetium-177
- Evaluating which radionuclides are best positioned to win across therapeutic efficacy, supply scalability, dosimetry flexibility, theranostic integration and global clinical applicability
- Challenging each isotope expert to defend why their radionuclide will become the hottest, most commercially impactful and most clinically transformative isotope over the next five years
- Understanding how radiation safety requirements differ between diagnostic and therapeutic radiopharmaceuticals, particularly as longer-lived radionuclides enter clinical use
- Exploring the key considerations for safely producing, handling and administering emerging therapeutic radionuclides across manufacturing and clinical environments
- Identifying the certification, compliance and operational requirements required to introduce new radionuclides into practice
